Novo Nordisk GLP-1 Lawsuits: What the Court Record Actually Shows

Marin & MurphySuper Lawyers® 2014–2024(888) 348-2735

Ozempic (GLP-1) Lawsuit — Free Case Review

Which Medications — and Which Injuries — Qualify

Eligibility differs by drug and by injury track. Check yours against the current criteria in minutes.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.

Did this happen to you — or someone you love?

Start your free case reviewTell us anyway

Answered 24/7 · Free & confidential · No fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney's fee is a percentage of the gross recovery, calculated before expenses are deducted.

(888) 348-2735

Partners

Matthew T. Marin & Stefanie A. Murphy

Super Lawyers® honorees · American Association for Justice members

Ozempic inquiries get a personal review — and an honest answer either way, free and without obligation.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Attorney Advertising.

Novo Nordisk is the manufacturer of Ozempic, Wegovy, and Rybelsus, and it is a defendant in both federal GLP-1 proceedings — MDL 3094 for stomach injuries and MDL 3163 for NAION vision loss — along with two New Jersey state-court multicounty litigations. No case against Novo Nordisk has been settled, and no jury has decided one. Marin & Murphy is currently accepting Ozempic (GLP-1) gastroparesis and NAION cases.

The products at issue

Novo Nordisk makes the three brand-name semaglutide products in this litigation: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management. All three are named on the Eastern District of Pennsylvania’s product list for the stomach-injury MDL, in the New Jersey multicounty litigation designations, and in the European regulator’s NAION safety review. They are also the only three brands meeting the referral criteria for both tracks; the Eli Lilly products meet the NAION criteria only.

The company also makes the older liraglutide products, Victoza and Saxenda. Those appear on neither MDL’s product list and are not in the referral criteria for either track — people who took them often assume they are covered, and as the record stands today, they are not.

Where Novo Nordisk is being sued

MDL 3094 — gastrointestinal injuries. Created February 2, 2024, transferring 17 actions to the Eastern District of Pennsylvania; before Judge Karen S. Marston since June 6, 2024. The first-filed and most-cited case is Bjorklund v. Novo Nordisk A/S (W.D. La. No. 2:23-cv-01020, filed August 2, 2023). Case Management Order No. 18 puts gastroparesis, ileus and intestinal obstruction, cholecystitis, and severe nausea and vomiting in scope. 4,025 actions were pending as of October 1, 2026.

MDL 3163 — NAION vision loss. Created December 15, 2025 before the same judge. Eli Lilly filed the motion that created it; Novo Nordisk supported centralization on September 12, 2025, while plaintiffs opposed it. Most founding cases name Novo Nordisk, including Kane v. Novo Nordisk A/S (D.N.J. No. 3:24-cv-11384, filed December 20, 2024). The proceeding grew from 20 actions to 247 as of the October 1, 2026 JPML report.

New Jersey state court. Two separate GLP-1 multicounty litigations — gastrointestinal and NAION — designated by Supreme Court order of October 16, 2025, both in Bergen County before Judge Gregg A. Padovano. The NAION application specifically concerned litigation against Novo Nordisk over Ozempic and Wegovy.

What the company is arguing

Novo Nordisk’s defense in the stomach-injury MDL runs along two live, undecided lines: that the claims are preempted by federal law and the labeling was adequate as a matter of law (Cross-Cutting Issue 2), and that plaintiffs cannot show these medications are capable of causing the injuries alleged (Cross-Cutting Issue 3). Its pending Rule 702 motions seek to exclude the opinions of plaintiffs’ gastroenterology experts (Dkts 681 and 682).

In the December 16, 2025 scheduling order the company also reserved preemption rights pending the outcome of an FDA Form 483 investigation. Plaintiffs have their own motions against defense experts. All of it is fully briefed and was heard at the September 14-18, 2026 hearing.

The regulatory record

• September 22, 2023 — FDA required an ileus (intestinal blockage) warning on the Ozempic label as a postmarketing-identified risk. Gastroparesis was not added as a named label term.
• July 3, 2024 — JAMA Ophthalmology published the Massachusetts Eye and Ear cohort study of more than 17,000 patients reporting substantially elevated NAION rates among patients prescribed semaglutide — the study that started the vision-loss litigation.
• June 6, 2025 — The European Medicines Agency’s safety committee concluded NAION is a very rare side effect of semaglutide medicines, affecting up to 1 in 10,000 people, and recommended adding it to European product information.
• September 9, 2025 — FDA issued a warning letter to Novo Nordisk Inc. (#716495) over promotional content it found misleading and omissive as to serious risks.
• As of September 23, 2026 — the US semaglutide label still carries no NAION warning, unlike the European Union, the United Kingdom, and Australia.

FDA adverse-event reports involving semaglutide

As of the July 30, 2026 data refresh, FDA’s FAERS database held 82,911 total reports and 36,179 serious reports for semaglutide, including 3,558 coded as impaired gastric emptying, 1,166 for intestinal obstruction, 632 for ileus, and 631 for optic ischaemic neuropathy, the term FAERS uses for NAION. Reports submitted to FDA are not verified and do not establish causation — they are voluntary, can duplicate one another, and respond to media attention and litigation as much as to clinical events.

Who may qualify

• Stomach injuries: brand-name Ozempic, Wegovy, or Rybelsus (not compounded or generic); gastroparesis confirmed by a gastric emptying study or gastric obstruction confirmed by objective testing; diagnosed while taking the medication or within about 30 days of stopping; an emergency-room visit or hospital admission; a diagnosis before December 31, 2024; age 75 or under at intake.
• NAION: brand-name Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, or Zepbound; an actual NAION diagnosis during or after use; some degree of permanent vision impairment.
• The August 2025 testing requirement applies to every gastroparesis claim. Most people diagnosed with gastroparesis were never sent for that test — a gap in ordinary clinical practice, not a reflection on the patient. “I’m not sure what testing I had” is a fine answer.
• This is a claim against Novo Nordisk, not your prescriber, pharmacist, or clinic. The prescriber’s records are usually the claimant’s best evidence.

The honest posture, stated without spin

No case against Novo Nordisk here has gone to trial, been decided by a jury, or been settled. There is no settlement program, no claims administrator, and no trial date in either MDL. The most consequential ruling so far favored the defense: on August 15, 2025 the court held that gastroparesis claims must rest on objective gastric-emptying testing and excluded two plaintiff diagnostic experts. A Rule 702 hearing on general causation, preemption, and warning adequacy was held September 14 through 18, 2026. In the NAION proceeding, early motion practice was granted July 2, 2026, and Case Management Order No. 14 (August 27, 2026) set the expert schedule, with plaintiffs’ expert reports due March 26, 2027.

One clarification, because headlines invite confusion: the July 2026 suit Novo Nordisk filed against Eli Lilly over GLP-1 advertising is a false-advertising dispute between competitors — not a personal-injury case, and not a settlement or verdict here.

Common questions

The companies & court files: Eli Lilly, the master complaint, and the lawsuit tracker.

Their GLP-1 drugs: Wegovy, Rybelsus, and compounded semaglutide.